Bing

SEARCH HISTORY

Gilead Sciences, Inc. (NASDAQ:GILD), the leader in the fast-expanding hepatitis C drugs market, has seen its stock price tumble 10% ever since leading investment research firm, Vetr Inc., downgraded the stock from a …
bidnessetc.com · 8/24/2015
Gilead Sciences
Trade-Ideas LLC identified Gilead ( GILD) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Gilead as such a stock due to the following factors: GILD has an average dollar-volume (as measured by average ...
The Street · 8/24/2015
Traders sold shares of Gilead Sciences (NASDAQ:GILD) on strength during trading on Thursday following insider selling activity, Market Beat Ratings reports. $282.09 million flowed into the stock on the tick-up and $412.41 million flowed out of the stock on ...
wkrb13.com · 8 hours ago
Gilead Sciences
More from Bing News
Traders sold shares of Gilead Sciences (NASDAQ:GILD) on strength during trading on Thursday following insider selling activity, Market Beat reports. $282.09 million flowed into the stock on the tick-up and $412.41 million flowed out of the stock on the ...
sleekmoney.com · 16 hours ago
Given the dramatic sell-off in biotech stocks (NASDAQ:IBB), including GILD, last week and overnight going into Monday's New York trading, as well as from their high point not long before that, some technical and fundamental discussion of the stock will be ...
Seeking Alpha · 8/24/2015
GILD
Gilead Sciences (NASDAQ:GILD) has earned an “A+” credit rating from analysts at Morningstar. The research firm’s “A+” rating indicates that the company is a low default risk. They also gave their stock a three …
Ticker Report · 8/25/2015
Short sellers were especially drawn to Biogen Inc (NASDAQ: BIIB), Gilead Sciences, Inc. (NASDAQ: GILD) and Vertex Pharmaceuticals Incorporated ... Short sellers watched the stock rise about 6 percent early in the month, only to give it all up by the ...
Benzinga · ByNelson Hem · 2 hours ago
Gilead Sciences
Year-to-date, the stock has more than doubled in value ... Moving along, heading into today's session, GILD was fresh off a three-day loss of 13.4% -- paring its year-to-date advance to less than 7%. At last check …
Schaeffer's Investment Research · 8/25/2015
NFLX
One of the S&P 500’s big winners for Wednesday August 26 was Gilead Sciences Inc. (GILD) as the company’s stock climbed 4.29% to $106.96 on volume of 15.36 million shares. The stock opened at $105.92 and saw an intraday low of $102.46 and …
Equities · 1 day ago
Amgen Inc. ( AMGN) and Gilead Sciences, Inc. ( GILD) are two California based bio-pharmaceutical companies that provide human therapeutics. Both companies focus and develop treatments and medicines to combat against different cancers, kidney …
NASDAQ · 8/14/2015

Gilead Sciences

Company
Gilead Sciences is an American biotechnology company that discovers, develops and commercializes therapeutics. For many y…
Gilead Sciences is an American biotechnology company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B, hepatitis C, or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonary diseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees. The company's name and logo refer to the Balm of Gilead.
Data from: Wikipedia